Literature DB >> 2457280

Selective inhibition of formation of suppressor glutamine tRNA in Moloney murine leukemia virus-infected NIH-3T3 cells by Avarol.

Y Kuchino1, S Nishimura, H C Schröder, M Rottmann, W E Müller.   

Abstract

Avarol is a sesquiterpenoid hydroquinone, which displays no inhibitory potencies on mammalian DNA polymerases alpha, beta, and gamma, on mammalian RNA polymerases I, II, and III, or on reverse transcriptases from Moloney murine leukemia virus (Mo-MuLV) and from HIV. For a further elucidation of the antiviral effect of Avarol, we used NIH-3T3 cells infected with Mo-MuLV as a model system. The results show that in uninfected NIH-3T3 cells Avarol (i) causes a 50% reduction of the growth rate only at the high concentration of 29.6 microM and (ii) is accumulated in the cytoplasm close to the nucleus. At the much lower concentrations of 1-3 microM, Avarol causes an almost complete inhibition of viral progeny release. Moreover, it is shown that at 3 microM Avarol, the increase of the Mo-MuLV-induced UAG suppressor glutamine tRNA (tRNA(UmUGGln) was reduced to the normal level. Dot blot hybridization studies revealed that Avarol displays no inhibitory activity on cellular and viral mRNA synthesis. Taking the processing pathway of viral polyprotein Pr180gag,pol to p80 (reverse transcriptase) as an example, our Western blotting experiments showed that the final maturation process, conversion of p110 to p80, is inhibited in Avarol-treated cells. From these data we conclude that Avarol prevents the suppression of the UAG termination codon at the gag-pol junction of the retroviral genome. The functional consequence of this event is very likely an inhibition of the readthrough of the retroviral protease gene which overlaps the pol and gag genes, resulting in the reduction of the protease synthesis which is necessary for the viral proliferation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457280     DOI: 10.1016/0042-6822(88)90596-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Nucleotide sequence of the human tRNA(UUGGln) gene.

Authors:  F Nemoto; T Okazaki; H Mizushima; W E Müller; Y Kuchino
Journal:  Nucleic Acids Res       Date:  1991-05-25       Impact factor: 16.971

Review 2.  Antiviral lead compounds from marine sponges.

Authors:  Sunil Sagar; Mandeep Kaur; Kenneth P Minneman
Journal:  Mar Drugs       Date:  2010-10-11       Impact factor: 5.118

Review 3.  Reactivity and biological activity of the marine sesquiterpene hydroquinone avarol and related compounds from sponges of the order Dictyoceratida.

Authors:  Dusan Sladić; Miroslav J Gasić
Journal:  Molecules       Date:  2006-01-31       Impact factor: 4.411

Review 4.  Antiviral therapy in human immunodeficiency virus infection.

Authors:  E Sandström
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

5.  HIV-1 designed to use different tRNAGln isoacceptors prefers to select tRNAThr for replication.

Authors:  Meng Li; Peter G Eipers; Na Ni; Casey D Morrow
Journal:  Virol J       Date:  2006-09-26       Impact factor: 4.099

Review 6.  Polycistronic animal virus mRNAs.

Authors:  C E Samuel
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1989

Review 7.  Ribosome gymnastics--degree of difficulty 9.5, style 10.0.

Authors:  J F Atkins; R B Weiss; R F Gesteland
Journal:  Cell       Date:  1990-08-10       Impact factor: 41.582

Review 8.  Marine sponges as pharmacy.

Authors:  Detmer Sipkema; Maurice C R Franssen; Ronald Osinga; Johannes Tramper; René H Wijffels
Journal:  Mar Biotechnol (NY)       Date:  2005-03-24       Impact factor: 3.619

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.